Andrew Rosenstein, MD
Gastroenterology · Baltimore, MDNPI 1275615486
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.6%), food and beverage and gifts — rather than concentrated in one kind of arrangement. AbbVie accounts for 64.3% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2019 at $6,320 and has fallen 89.8% since, to $642 in 2025.
Across 336 payments — averaging $41.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$9K
- Johnson & Johnson$1K
- Takeda Pharmaceuticals U.S.A., Inc.$553
- Braintree Laboratories, Inc.$497
- Bristol Myers Squibb$462
- Amgen$416
- plus $2K from 24 others
What the payments were for
- Speaking & faculty fees$7,12552%
- Food & beverage$6,31046%
- Education$470%
- Gifts$3292%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 86 | $8,880 |
| Johnson & Johnson | 72 | $1,183 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $553 |
| Braintree Laboratories, Inc. | 10 | $497 |
| Bristol Myers Squibb | 30 | $462 |
| Amgen(2 entities) | 19 | $416 |
| Pfizer | 17 | $341 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $195 |
| Ardelyx, Inc. | 8 | $164 |
| Nestle Healthcare Nutrition Inc. | 9 | $125 |
| Sanofi | 4 | $113 |
| Gilead | 6 | $113 |
| Aimmune Therapeutics, Inc. | 4 | $97 |
| Lilly USA, LLC | 5 | $92 |
| Intercept Pharmaceuticals, Inc. | 4 | $85 |
| QOL Medical, LLC | 4 | $82 |
| Regeneron Healthcare Solutions, Inc. | 2 | $61 |
| Ironwood Pharmaceuticals, Inc | 3 | $55 |
| Ferring Pharmaceuticals Inc. | 2 | $39 |
| Romark Laboratories, LC | 2 | $36 |
| Tersera Therapeutics LLC | 1 | $31 |
| Madrigal Pharmaceuticals | 1 | $28 |
| Olympus America Inc. | 2 | $28 |
| Laborie Medical Technologies Corp. | 1 | $25 |
| Caris MPI, Inc. | 1 | $25 |
| Fresenius Kabi USA, LLC | 1 | $22 |
| Boehringer Ingelheim | 1 | $19 |
| Capsovision, Inc. | 1 | $17 |
| Merck | 1 | $16 |
| Concordia Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Humira$4,875
- SUPREP BOWEL PREP$213
- KRYSTEXXA$118
How this compares
$13,812 in reported general payments places this provider in the 85th percentile of 455 gastroenterology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 48 | $145,763 |
| XifaxanRifaximin | 31 | $99,651 |
| Mesalamine | 45 | $30,963 |
| LinzessLinaclotide | 14 | $17,802 |
| Dexlansoprazole DrDexlansoprazole | 30 | $10,535 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 90 | $10,505 |
| Mesalamine ErMesalamine | 33 | $9,915 |
| NexiumEsomeprazole Magnesium | 11 | $9,851 |
| Budesonide DrBudesonide | 73 | $7,811 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 42 | $7,180 |
| Esomeprazole Magnesium | 80 | $6,956 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 60 | $3,743 |
| Pantoprazole Sodium | 211 | $3,666 |
| Balsalazide Disodium | 23 | $3,277 |
| Budesonide EcBudesonide | 25 | $3,094 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $8,880 | $163,56562 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $195 | $99,65131 claims |
| Braintree Laboratories, Inc.Suflave, Sutab | $497 | $13,144107 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $39 | $7,18042 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 455 gastroenterology providers in Maryland.
Other gastroenterology in Baltimore
- Sergey KantsevoyBaltimore$1.1M
- Anurag MaheshwariBaltimore$803K
- Aline Charabaty PishvaianBaltimore$631K
- Mouen KhashabBaltimore$440K
- Raymond CrossBaltimore$341K
- Paul ThuluvathBaltimore$231K
- Niraj JaniBaltimore$214K
- Aminur KhanBaltimore$118K
- Eric GoldbergBaltimore$110K
- Saowanee NgamruengphongBaltimore$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.